H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation

References

• Vemula SV, Zhao J, Liu J, Wang X, Biswas S, Hewlett I. Current approaches for diagnosis of influenza virus infections in humans. Viruses. 2016;8(4):96. doi:10.3390/v8040096. PMID:27077877.
   PubMed Web of Science ®Google Scholar
• Shim JM, Kim J, Tenson T, Min JY, Kainov DE. Influenza Virus Infection, Interferon Response, Viral Counter-Response, and Apoptosis. Viruses. 2017;9(8):223. doi:10.3390/v9080223.
   Web of Science ®Google Scholar
• Alymova IV, York IA, Air GM, Cipollo JF, Gulati S, Baranovich T, Kumar A, Zeng H, Gansebom S, McCullers JA. Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence. Scientific Rep. 2016;6:36216.
   PubMed Web of Science ®Google Scholar
• Yang J, Liu S, Du L, Jiang S. A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action. Rev Med Virology. 2016;26(4):242–50. doi:10.1002/rmv.1879.
   PubMed Web of Science ®Google Scholar
• Lin Y, Wharton SA, Whittaker L, Dai M, Ermetal B, Lo J, Pontoriero A, Baumeister E, Daniels RS, McCauley JW. The characteristics and antigenic properties of recently emerged subclade 3C. 3a and 3C. 2a human influenza A (H3N2) viruses passaged in MDCK cells. Influenza Other Respir Viruses. 2017;11(3):263–74. doi:10.1111/irv.12447. PMID:28164446.
   PubMed Web of Science ®Google Scholar
• Melidou A, Gioula G, Exindari M, Ioannou E, Gkolfinopoulou K, Georgakopoulou T, Tsiodras S, Papa A. Ιnfluenza A (H3N2) genetic variants in vaccinated patients in northern Greece. J Clinical Virology. 2017;94:29–32. doi:10.1016/j.jcv.2017.07.003.
   PubMed Web of Science ®Google Scholar
• Blackburne BP, Hay AJ, and Goldstein RA. Changing selective pressure during antigenic changes in human influenza H3. PLoS pathogens. 2008;4(5):e1000058. doi:10.1371/journal.ppat.1000058. PMID:18451985.
   PubMed Web of Science ®Google Scholar
• Chambers BS, Li Y, Hodinka RL, Hensley SE. Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses. J Virology. 2014;88(18):10986–9. doi:10.1128/JVI.01077-14. PMID:24991002.
   PubMed Web of Science ®Google Scholar
• Pavlova S, D'Alessio F, Houard S, Remarque EJ, Stockhofe N, Engelhardt OG. Workshop report: Immunoassay standardisation for “universal” influenza vaccines. Influenza and Other Respir Viruses. 2017;11(3):194–201. doi:10.1111/irv.12445. PMID:28146323.
   PubMed Web of Science ®Google Scholar
• Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic acid receptors. J Virology. 2012;86(24):13371–83. doi:10.1128/JVI.01426-12. PMID:23015718.
   PubMed Web of Science ®Google Scholar
• Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, Lackenby A, Daniels R, Hay A. Neuraminidase receptor binding variants of human influenza A (H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virology. 2010;84(13):6769–81. doi:10.1128/JVI.00458-10. PMID:20410266.
   PubMed Web of Science ®Google Scholar
• Bouvier NM and Palese P. The biology of influenza viruses. Vaccine. 2008;26:D49−53. doi:10.1016/j.vaccine.2008.07.039. PMID:19230160.
   PubMed Web of Science ®Google Scholar
• Westgeest KB, Russell CA, Lin X, Spronken MI, Bestebroer TM, Bahl J, van Beek R, Skepner E, Halpin RA, de Jong JC, et al., Genomewide analysis of reassortment and evolution of human influenza A (H3N2) viruses circulating between 1968 and 2011. J Virology. 2014;88(5):2844–57. doi:10.1128/JVI.02163-13. PMID:24371052.
   PubMed Web of Science ®Google Scholar
• Huang Z-Z, Yu L, Huang P, Liang LJ, Guo Q. Charged amino acid variability related to N-glyco-sylation and epitopes in A/H3N2 influenza: Hem-agglutinin and neuraminidase. PloS one. 2017;12(7):e0178231. doi:10.1371/journal.pone.0178231. PMID:28708860.
   PubMed Web of Science ®Google Scholar
• Peng W, de Vries RP, Grant OC, Thompson AJ, McBride R, Tsogtbaatar B, Lee PS, Razi N, Wilson IA, Woods RJ, et al., Recent H3N2 viruses have evolved specificity for extended, branched human-type receptors, conferring potential for increased avidity. Cell Host & Microbe. 2017;21(1):23–34. doi:10.1016/j.chom.2016.11.004.
   PubMed Web of Science ®Google Scholar
• Ushirogawa H, Naito T, Tokunaga H, Tanaka T, Nakano T, Terada K, Ohuchi M, Saito M. Re-emergence of H3N2 strains carrying potential neutralizing mutations at the N-linked glycosylation site at the hemagglutinin head, post the 2009 H1N1 pandemic. BMC Infectious Dis. 2016;16(1):380. doi:10.1186/s12879-016-1738-1.
   PubMedGoogle Scholar
• Shao W, Li X, Goraya MU, Wang S, Chen JL. Evolution of Influenza A Virus by Mutation and Re-Assortment. International J Molecular Sci. 2017;18(8):1650. doi:10.3390/ijms18081650.
   PubMed Web of Science ®Google Scholar
• Hooper KA, Crowe JE, and Bloom JD. Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice. J Virology. 2015;89(7):3737–45. doi:10.1128/JVI.00012-15. PMID:25609803.
   PubMed Web of Science ®Google Scholar
• Medeiros R, Escriou N, Naffakh N, Manuguerra JC, van der Werf S. Hemagglutinin residues of recent human A (H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes. Virology. 2001;289(1):74–85. doi:10.1006/viro.2001.1121. PMID:11601919.
   PubMed Web of Science ®Google Scholar
• Yang H, Carney PJ, Chang JC, Guo Z, Villanueva JM, Stevens J. Structure and receptor binding preferences of recombinant human A (H3N2) virus hemagglutinins. Virology. 2015;477:18–31. doi:10.1016/j.virol.2014.12.024. PMID:25617824.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Fujisaki S, Shirakura M, Watanabe S, Odagiri T, Ito K, Sato H. Molecular dynamics simulation of the influenza A (H3N2) hemagglutinin trimer reveals the structural basis for adaptive evolution of the recent epidemic clade 3C. 2a. Frontiers in Microbiology. 2017;8:548. doi:10.3389/fmicb.2017.00584.
   PubMed Web of Science ®Google Scholar
• Van Poucke S, Doedt J, Baumann J, Qiu Y, Matrosovich T, Klenk HD, Van Reeth K, Matrosovich M. Role of Substitutions in the Hemagglutinin in the Emergence of the 1968 Pandemic Influenza Virus. J Virology. 2015;89(23):12211–6. doi:10.1128/JVI.01292-15. PMID:26378170.
   PubMed Web of Science ®Google Scholar
• Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, Skepner E, Lewis NS, Spronken MI, Russell CA, et al., Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976–9. doi:10.1126/science.1244730. PMID:24264991.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y and Suzuki Y. Compensatory evolution of net-charge in influenza A virus hemagglutinin. PloS one. 2012;7(7):e40422. doi:10.1371/journal.pone.0040422. PMID:22808159.
   PubMed Web of Science ®Google Scholar
• Asaoka N, Tanaka Y, Sakai T, Fujii Y, Ohuchi R, Ohuchi M. Low growth ability of recent influenza clinical isolates in MDCK cells is due to their low receptor binding affinities. Microbes Infect. 2006;8(2):511–9. doi:10.1016/j.micinf.2005.08.006. PMID:16300986.
   PubMed Web of Science ®Google Scholar
• Parker L, Wharton SA, Martin SR, Cross K, Lin Y, Liu Y, Feizi T, Daniels RS, McCauley JW. Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. J Gen Virology. 2016;97(6):1333–44. doi:10.1099/jgv.0.000457.
   PubMedGoogle Scholar
• Hervé P-L, Lorin V, Jouvion G, Da Costa B, Escriou N. Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity. Virology. 2015;486:134–45. doi:10.1016/j.virol.2015.08.033. PMID:26433051.
   PubMed Web of Science ®Google Scholar
• Harvala H, Frampton D, Grant P, Raffle J, Ferns RB, Kozlakidis Z, Kellam P, Pillay D, Hayward A, Nastouli E. Emergence of a novel subclade of influenza A (H3N2) virus in London, December 2016 to January 2017. Eurosurveillance. 2017;22(8):30466. doi:10.2807/1560-7917.ES.2017.22.8.30466.
   Web of Science ®Google Scholar
• Park AW, Daly JM, Lewis NS, Smith DJ, Wood JL, Grenfell BT. Quantifying the impact of immune escape on transmission dynamics of influenza. Science. 2009;326(5953):726–8. doi:10.1126/science.1175980. PMID:19900931.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Sabaiduc S, Chambers C, Eshaghi A, Gubbay JB, Krajden M, Drews SJ, Martineau C, De Serres G, Dickinson JA, et al., Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A (H3N2) clade 3C. 2a viruses. Eurosurveillance. 2016;21(3):30122. doi:10.2807/1560-7917.ES.2016.21.3.30112.
   Web of Science ®Google Scholar
• Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014–2015 influenza season. Cell Rep. 2015;12(1):1–6. doi:10.1016/j.celrep.2015.06.005. PMID:26119736.
   PubMed Web of Science ®Google Scholar
• Wu NC, Zost SJ, Thompson AJ, et al., A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathogens. 2017;13(10):e1006682. doi:10.1371/journal.ppat.1006682. PMID:29059230.
   PubMed Web of Science ®Google Scholar
• Wang B, Russell ML, Brewer A, et al., Single radial haemolysis compared to haemagglutinin inhibition and microneutralization as a correlate of protection against influenza A H3N2 in children and adolescents. Influenza and Other Respir Viruses. 2017;11(3):283–8. doi:10.1111/irv.12450. PMID:28218983.
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of serological techniques for influenza vaccine evaluation: past, present and future. Vaccines. 2014;2(4):707–34. doi:10.3390/vaccines2040707. PMID:26344888.
   PubMedGoogle Scholar
• Gulati S, Smith DF, Cummings RD, Couch RB, Griesemer SB, St George K, Webster RG, Air GM. Human H3N2 influenza viruses isolated from 1968 to 2012 show varying preference for receptor substructures with no apparent consequences for disease or spread. PloS one. 2013;8(6):e66325. doi:10.1371/journal.pone.0066325. PMID:23805213.
   PubMed Web of Science ®Google Scholar
• Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, Christodoulou E, Walker PA, Liu J, Skehel JJ, et al., Evolution of the receptor binding properties of the influenza A (H3N2) hemagglutinin. Proc Natl Academy of Sciences. 2012;109(52):21474–9. doi:10.1073/pnas.1218841110.
   PubMed Web of Science ®Google Scholar
• Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG, Fukuda K, Grohmann G, Hay A, Kelso A, Klimov A, et al., Epidemiological, antigenic and genetic characteristics of seasonal influenza A (H1N1), A (H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season. Vaccine. 2010;28(5):1156–67. doi:10.1016/j.vaccine.2009.11.043. PMID:20004635.
   PubMed Web of Science ®Google Scholar
• Oh DY, Barr IG, Mosse JA, Laurie KL MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clinical Microbiology. 2008;46(7):2189–94. doi:10.1128/JCM.00398-08.
   PubMed Web of Science ®Google Scholar
• Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the α-2, 6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virology. 2003;77(15):8418–25. doi:10.1128/JVI.77.15.8418-8425.2003. PMID:12857911.
   PubMed Web of Science ®Google Scholar
• Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virology. 2004;78(22):12665–7. doi:10.1128/JVI.78.22.12665-12667.2004. PMID:15507653.
   PubMed Web of Science ®Google Scholar
• Mishin VP, Sleeman K, Levine M, Carney PJ, Stevens J, Gubareva LV. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A (H3N2) viruses. Antiviral Res. 2014;101:93–96. doi:10.1016/j.antiviral.2013.11.001. PMID:24239666.
   PubMed Web of Science ®Google Scholar
• Colman PM, Varghese J, and Laver W. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983;303(5912):41–44. doi:10.1038/303041a0. PMID:6188957.
   PubMed Web of Science ®Google Scholar
• van Baalen CA, Jeeninga RE, Penders GH, van Gent B, van Beek R, Koopmans MP, Rimmelzwaan GF. ViroSpot microneutralization assay for antigenic characterization of human influenza viruses. Vaccine. 2017;35(1):46–52. doi:10.1016/j.vaccine.2016.11.060. PMID:27899226.
   PubMed Web of Science ®Google Scholar
• Lin Y, Gu Y, and McCauley JW. Optimization of a Quantitative Micro-neutralization Assay. Journal of visualized experiments: JoVE. 2016(118):54897.
   Web of Science ®Google Scholar
• Sullivan K, Kloess J, Qian C, Bell D, Hay A, Lin YP, Gu Y. High throughput virus plaque quantitation using a flatbed scanner. J Virological Methods. 2012;179(1):81–89. doi:10.1016/j.jviromet.2011.10.003.
   PubMed Web of Science ®Google Scholar